George Petrescu

Dr. George Petrescu

"Bagdasar-Arseni" Clinical Emergency Hospital, Bucharest, Romania
+1
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 April 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Stefan Sebastian BusnatuStefan Sebastian Busnatu
Stefan Sebastian Busnatu
Adelina-Gabriela NiculescuAdelina-Gabriela Niculescu
Adelina-Gabriela Niculescu
ABAlexandra Bolocan
Alexandra Bolocan
GPGeorge Petrescu
George Petrescu
DPDan Nicolae Păduraru
Dan Nicolae Păduraru
HMHenrique Martins
Henrique Martins
Artificial intelligence has the potential to revolutionize modern society in all its aspects. Encouraged by the variety and vast amount of data that can be gathered from patients (e.g., medical images, text, and electronic health records), researchers have recently increased their interest in developing AI solutions for clinical care. Moreover, a diverse repertoire of methods can be chosen towards creating performant models for use in medical applications, ranging from disease prediction, diagnosis, and prognosis to opting for the most appropriate treatment for an individual patient. In this respect, the present paper aims to review the advancements reported at the convergence of AI and clinical care. Thus, this work presents AI clinical applications in a comprehensive manner, discussing the recent literature studies classified according to medical specialties. In addition, the challenges and limitations hindering AI integration in the clinical setting are further pointed out.

29 May 2019 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
GPGeorge Petrescu
George Petrescu
ASAlexandru-Anton Sabo
Alexandru-Anton Sabo
LTLigia-Iulia Torsin
Ligia-Iulia Torsin
George CalinGeorge Calin
George Calin
MDMihnea Dragomir
Mihnea Dragomir
Because of the complexity of the blood-brain barrier (BBB), brain tumors, especially the most common and aggressive primary malignant tumor type arising from the central nervous system (CNS), glioblastoma, remain an essential challenge regarding diagnostic and treatment. There are no approved circulating diagnostic or prognostic biomarkers, nor novel therapies like immune checkpoint inhibitors for glioblastoma, and chemotherapy brings only minimal survival benefits. The development of molecular biology led to the discovery of new potential diagnostic tools and therapeutic targets, offering the premise to detect patients at earlier stages and overcome the current poor prognosis. One potential diagnostic and therapeutic breakthrough might come from microRNAs (miRNAs). It is well-known that miRNAs play a role in the initiation and development of various types of cancer, including glioblastoma. The review aims to answer the following questions concerning the role of RNA theranostics for brain tumors: (1) which miRNAs are the best candidates to become early diagnostic and prognostic circulating biomarkers?; (2) how to deliver the therapeutic agents in the CNS to overcome the BBB?; (3) which are the best methods to restore/inhibit miRNAs? Because of the proven roles played by miRNAs in gliomagenesis and of their capacity to pass from the CNS tissue into the blood or cerebrospinal fluid (CSF), we propose miRNAs as ideal diagnostic and prognostic biomarkers. Moreover, recent advances in direct miRNA restoration (miRNA mimics) and miRNA inhibition therapy (antisense oligonucleotides, antagomirs, locked nucleic acid anti-miRNA, small molecule miRNA inhibitors) make miRNAs perfect candidates for entering clinical trials for glioblastoma treatment.

22 October 2019 in Langenbeck's Archives of Surgery
Verified
Journal Article
Closed access
PDF file
MDMihnea P. Dragomir
Mihnea P. Dragomir
ASAlexandru A. Sabo
Alexandru A. Sabo
GPGeorge Petrescu
George Petrescu
YLYongfeng Li
Yongfeng Li
TDTraian Dumitrascu
Traian Dumitrascu

Verified
Journal Article
Open access
PDF file
LTLigia-Iulia Torsin
Ligia-Iulia Torsin
GPGeorge Petrescu
George Petrescu
ASAlexandru-Anton Sabo
Alexandru-Anton Sabo
BCBaoqing Chen
Baoqing Chen
FBFelix Mircea Brehar
Felix Mircea Brehar
MDMihnea Dragomir
Mihnea Dragomir
Currently, for seemingly every type of cancer, dysregulated levels of non-coding RNAs (ncRNAs) are reported and non-coding transcripts are expected to be the next class of diagnostic and therapeutic tools in oncology. Recently, alterations to the ncRNAs transcriptome have emerged as a novel hallmark of cancer. Historically, ncRNAs were characterized mainly as regulators and little attention was paid to the mechanisms that regulate them. The role of modifications, which can control the function of ncRNAs post-transcriptionally, only recently began to emerge. Typically, these modifications can be divided into reversible (i.e., chemical modifications: m5C, hm5C, m6A, m1A, and pseudouridine) and non-reversible (i.e., editing: ADAR dependent, APOBEC dependent and ADAR/APOBEC independent). The first research papers showed that levels of these modifications are altered in cancer and can be part of the tumorigenic process. Hence, the aim of this review paper is to describe the most common regulatory modifications (editing and chemical modifications) of the traditionally considered “non-functional” ncRNAs (i.e., microRNAs, long non-coding RNAs and circular RNAs) in the context of malignant disease. We consider that only by understanding this extra regulatory layer it is possible to translate the knowledge about ncRNAs and their modifications into clinical practice.

18 March 2022 in Frontiers in Oncology
Verified
Journal Article
Open access
RRRoxana Radu
Roxana Radu
GPGeorge Petrescu
George Petrescu
RGRadu M. Gorgan
Radu M. Gorgan
FBFelix M. Brehar
Felix M. Brehar
GFAPδ, the delta isoform of the glial fibrillary acidic protein, is mainly expressed in the subventricular zone of the brain, together with other neural stem cell markers like nestin. The authors of this paper were among the first that described in detail the expression of GFAPδ and its correlation with malignancy and invasiveness in cerebral astrocytoma. Later, several papers confirmed these findings, showing that the alternative splice variant GFAPδ is overexpressed in glioblastoma (CNS WHO grade 4) compared with lower grade gliomas. Other studies suggested that a high GFAPδ/α ratio is associated with a more malignant and invasive behavior of glioma cells. Moreover, the changing of GFAPδ/α ratio affects the expression of high-malignant genes. It is now suggested that discriminating between predominant GFAP isoforms, GFAPδ or GFAPα, is useful for assessing the malignancy state of astrocytoma, and may even contribute to the classification of gliomas. Therefore, the purpose of this paper is to review the literature with emphasize on the role of GFAPδ as a potential biomarker, and as a possible therapeutic target in glioblastoma.

1 January 2016 in Chirurgia
Verified
Journal Article
Closed access
MDMihnea Dragomir
Mihnea Dragomir
GPGeorge Petrescu
George Petrescu
GMGraţiela Elena Manga
Graţiela Elena Manga
George CalinGeorge Calin
George Calin
CVCătălin Vasilescu
Cătălin Vasilescu
The risks that arise after splenectomy can be divided in infectious and non-infectious. The link between splenectomy and these hazards remains partially unknown. Host defense against infection is altered after splenectomy and such individuals develop sepsis more easily and the infection has a fulminant course. Splenectomy is also a potential risk factor for several vascular complications that result from partial or total obstruction of an arterial or venous blood vessel. Furthermore, pulmonary hypertensioncan be a severe and sometimes fatal complication following splenectomy. Some authors also consider that malignancies, diabetes mellitus and acute pancreatitis are non-infectious complications after splenectomy. The most feared complication for splenectomized patients remains sepsis. The pathophysiology of sepsis is still controversial. Death in sepsis can occur due to either hyper-inflammation or immune paralysis. Multiple experimental evidences link cellular and viral microRNAs with sepsis. We presume that miRNAs are also associated with the immunosuppression of the asplenic patients which leads to the high risk of deadly sepsis. Studying the expression level of circulating miRNAs in asplenic patients could help us better understand the postsplenectomy immunosuppression and develop new diagnostic and therapeutic tools.